Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients

British Journal of Haematology

Volumn 158, Issue 1, 2012, Pages 149-152

  Spira, Jack ^a   Plyushch, Olga ^b   Andreeva, Tatiana ^c   Zorenko, Vladimir ^b   Zozulya, Nadezhda ^b   Velichkoi, Irena ^b   Zalepukhina, Olga Ervinovna ^c   Yatuv, Rivka ^d   Baru, Moshe ^d  

^a Recoly NV ^*  (Netherlands)

^b NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^c Haemophilia Centre   (Russian Federation)

^d Omri Laboratories Ltd   (Israel)

Author keywords

Factor VIII; Haemophilia A; Long acting; PEGylated liposomes; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; DOXORUBICIN; LIPOSOME; LONG ACTING DRUG;

ADULT; BLEEDING; CLINICAL ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEMOPHILIA A; HOME CARE; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; FACTOR VIII; HEMOPHILIA A; HUMANS; LIPOSOMES; YOUNG ADULT;

EID: 84862256922     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09115.x     Document Type: Letter

References (10)

1. Baru, M., Carmel-Goren, L., Barenholz, Y., Dayan, I., Ostropolets, S., Slepoy, I., Gvirtzer, N., Fukson, V. & Spira, J. (2005) Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thrombosis and Haemostasis, 93, 1061-1068.
2. Collins, P., Faradji, A., Morfini, M., Enriquez, M.M. & Schwartz, L. (2010) Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. Journal of Thrombosis and Haemostasis, 8, 83-89.
3. Dayan, I., Robinson, M & Baru, M. (2009) Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes. Haemophilia, 15, 1006-1013.
4. Den Uijl, I., Mauser-Bunschoten, E.P., Roosendaal, G., Schutgens, R. & Fischer, K. (2009) Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment. Haemophilia, 15, 1215-1218.
5. Manco-Johnson, M.J., Abshire, TC, Shapiro, A.D., Riske, B., Hacker, M.R., Kilcoyne, R., Ingram, J.D., Manco-Johnson, M.L., Funk, S., Jacobson, L., Valentino, L.A., Hoots, W.K., Buchanan, G.R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G.A., Thompson, A.A., McRedmond, K., Soucie, J.M., Austin, H. & Evatt, B.L. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. New England Journal of Medicine, 357, 535-544.
6. Pan, J., Liu, T., Kim, J.Y., Zhu, D., Patel, C., Cui, Z.H., Zhang, X., Newgren, J.O., Reames, A., Canivel, D., Jesmok, G., Pierce, G.F., Sommer, J.M. & Jiang, H. (2009) Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood, 114, 2802-2811.
7. Powell, J.S., Nugent, D.J., Harrison, J.A., Soni, A., Luk, A., Stass, H. & Gorina, E. (2008) Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. Journal of Thrombosis and Haemostasis, 6, 277-283.
8. Shapiro, A.D. (2007) Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. Vascular Health and Risk Management, 3, 555-565.
9. Spira, J., Plyushch, O.P., Andreeva, T.A. & Andreev, Y. (2006) Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood, 108, 3668-3673.
10. Spira, J., Plyushch, O.P., Andreeva, T.A. & Khametova, R.N. (2008) Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thrombosis and Haemostasis, 100, 429-434.